Citi added an “upside 90-day catalyst watch” on shares of Guardant Health (GH) while keeping a Buy rating on the name with a $150 price target Citi sees upside to Q1 estimates from higher selling prices and notes the stock’s multiple has pulled back.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target lowered to $90 from $110 at Evercore ISI
- Guardant Health added to Q2 Tactical Ideas List at Wells Fargo
- Guardant Health announces evidence generated from InfinityAI
- Guardant Health, Verana Health announce new partnership
- Insiders Shake Up Guardant, Ovintiv, Redwire, Builders FirstSource, Permian